Table 3.

Prognostic value of the IHC4 score and clinicopathological clinical factors as assessed in univariate and multivariable analysis

	Univariate				Multivariableb (N = 350)
	N	HR	95% CI (HR)	P	HR	95% CI (HR)	P
Age (year) (N = 430)
< 65	257	1.00
≥ 65	173	1.37	0.85–2.21	0.20
Nodes (N = 395)
Negative	193	1.00		< 0.001	1.00		<0.001
1–3 N+	143	1.92	1.02–3.64		1.59	0.79–3.20
>3 N+	59	6.13	3.29–11.43		4.24	2.11–8.55
Tumour size (cm) (N = 427)
≤ 1	52	1.00		< 0.001
>1– ≤ 2	194	1.90	0.56–6.38		3.93	0.52–29.55	0.03
>2– ≤3	127	3.63	1.09–12.05		5.23	0.69–39.53
>3	54	6.47	1.91–21.88		9.11	1.19–69.91
Tumour grade (N = 384)
GI	97	1.00		0.46
GII	209	1.31	0.64–2.68
GIII	78	1.68	0.74–3.84
IHC4a (N = 430)	430	1.01	1.00–1.01	0.03	1.00	1.00–1.01	0.07
Treatment (N = 430)
Tamoxifen	208	1.00			1.00
Exemestane	222	0.95	0.59–1.53	0.83	0.87	0.50–1.53	0.64b

^a The IHC4 score was calculated using the Cuzick et al. algorithm and comprised ER, PR, HER2 and Ki67

^bThe multivariable model was adjusted for treatment group and was selected using a stepwise backward selection at the 10% level